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Abstract: Iron is essential in oxygen transport and participates in many enzymatic systems 
in the body, with important roles in collagen synthesis and vitamin D metabolism. The 
relationship between iron and bone health comes from clinical observations in iron overload 
patients who suffered bone loss. The opposite scenario—whether iron deficiency, with or 
without anemia, affects bone metabolism—has not been fully addressed. This is of great 
interest, as this nutrient deficiency is a worldwide public health problem and at the same 
time osteoporosis and bone alterations are highly prevalent. This review presents current 
knowledge on nutritional iron deficiency and bone remodeling, the biomarkers to evaluate 
iron status and bone formation and resorption, and the link between iron and bone 
metabolism. Finally, it is hypothesized that chronic iron deficiency induces bone resorption 
and risk of osteoporosis, thus complete recovery from anemia and its prevention should be 
promoted in order to improve quality of life including bone health. Several mechanisms are 
suggested; hence, further investigation on the possible impact of chronic iron deficiency on 
the development of osteoporosis is needed. 
Keywords: iron deficiency; anemia; iron overload; bone remodeling; bone health; 
osteoporosis; vitamin D; bone formation; bone resorption 
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1. Iron in Human Health 
Iron is the fourth most common element on earth and is a biologically essential component of every 
living organism [1]. The body requires iron for oxygen transport, in particular by the proteins 
hemoglobin and myoglobin, and for the formation of heme enzymes and other iron-containing enzymes 
involved in electron transfer and oxidation-reduction reactions [2]. Approximately 73% of the body’s 
iron is in the hemoglobin of circulating red cells and in the muscle protein myoglobin; 12% is in iron 
storage proteins, and another 15% is critically important in dozens of enzymes that are essential for the 
functioning of all cells and tissues [3].  
Iron deficiency is so widespread in humans that it affects all ethnic groups, in both industrialized and 
non-industrialized countries, with major consequences for human health and socioeconomic 
development [1–4]. A low iron status can reduce physical activity and increase susceptibility to 
infections. Moreover, iron deficiency, even in the absence of anemia, can cause fatigue and reduce work 
performance [5]. It has been observed in young women that a good iron status enhances various 
components of wellbeing [6]. 
1.1. Prevalence and Risk Factors of Iron Deficiency Anemia 
The World Health Organization (WHO) defines anemia as a condition in which the number of red 
blood cells or their oxygen-carrying capacity is insufficient to meet physiological needs, which vary by 
age, sex, altitude, smoking, and pregnancy status. Iron deficiency anemia is the most common form of 
anemia [4]. 
Globally, iron deficiency anemia affects between 1.5 and 1.7 billion people, which is 24.8%  
of the world population. Even though the highest prevalence is in preschool-age children (47.4%,  
283–303 million children), the population group with the greatest number of individuals affected is 
women of childbearing age (30.2%, 446–491 million women) [4].  
Iron deficiency results when iron losses or requirements exceed absorption, and is often 
multifactorial. It is well established that low iron consumption and low bioavailability of dietary iron are 
crucial in the development of iron deficiency [5]. The bioavailability of non-heme iron, the main source 
of iron from most diets (approximately 85%–90% of total iron intake), is affected by the presence of 
several dietary components. Non-heme iron absorption is enhanced principally by animal tissue 
(especially red meat) and ascorbic acid [7,8], whereas phytic acid, calcium, and polyphenols are the main 
inhibitors [7,9–12].  
Menstrual blood loss contributes to a negative iron balance in women of childbearing age [13,14]. 
Therefore, these women constitute an important risk group due to the additional iron demands of 
menstruation and pregnancy [13–15]. Other factors in postmenopausal woman and men are 
malabsorption (i.e., celiac disease), ulcerative colitis, use of nonsteroidal anti-inflammatory drugs, or 
gastrointestinal blood loss [16]. 
In addition, genetic factors are determinant in the development of iron deficiency anemia. Preliminary 
absorption assays and genome-wide association studies identified genetic variants that potentially could 
be genetic markers of iron deficiency [17,18]. Blanco-Rojo et al. (2011) [19] observed in Spanish 
menstruating women that a large percentage of the genetic variation of serum transferrin was explained 
by two single nucleotide polymorphisms (SNPs) located in the transferrin (Tf) gene and two in the 
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hemochromatosis (HFE) gene. Only one of them, located in an intronic region of the Tf gene (SNP 
rs3811647), was associated with iron deficiency and affected transcription [20], while the others appear 
to have compensating effects, particularly the very well-known Cys282Tyr substitution in HFE, 
suggesting that this genetic factor that is characteristic of iron overload protects from iron deficiency 
anemia. Other genetic variants, such us SNP rs1375515 located in a calcium channel gene, are also 
related to hematological iron markers and clinical phenotypes [21]. The study of the influence of dietary, 
menstruation, and genetic factors combined reveals that meat, menstrual blood loss, and the C282Y 
genetic variant determine iron status in young women [13]. 
1.2. Functional Consequences of Iron Deficiency  
Iron deficiency, even in absence of anemia, adversely affects: 
• The cognitive performance and physical growth of infants, preschool-, and school-aged  
children [22]. Among the cognitive impairments, those referring to attention span, intelligence, 
and sensory perception functions are well known, as well as those associated with emotions and 
behavior [23]. 
• The immune status and morbidity from infections of all age groups [24]. 
• The use of energy sources by muscles and thus the physical capacity, motor skills, work, and 
athletic performance of adolescents and adults of all age groups [22–25].  
• During pregnancy, iron deficiency anemia increases perinatal risks for mothers and neonates and 
increases overall infant mortality [22]. 
1.3. Evaluation of Iron Status   
Iron status is characterized by three phases: iron depletion, iron deficiency (iron deficient 
erythropoiesis or non-anemic iron deficiency), and iron deficiency anemia [10,26]. The terminology and 
cut-off values for the biochemical measures of each of these stages vary as some functional changes may 
occur in the absence of anemia (Figure 1). 
In the first phase (iron depletion), body iron stores are depleted, which can be detected by a reduction 
in serum ferritin. The second phase (iron deficiency) is characterized by the reduction in serum ferritin 
and serum iron, and an increase in serum transferrin and its receptor (sTfR) in an attempt to enhance 
iron transport to tissues, but transferrin saturation falls. At this stage some iron-dependent functions, like 
erythropoiesis, are compromised. In the final phase (iron deficiency anemia), oxygen supply to tissues 
is impaired, which is reflected by a decrease in hemoglobin concentrations, hematocrit, mean 
corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum ferritin, serum iron, and 
transferrin saturation [10].  
Table 1 shows the hemoglobin cut-off values to diagnose anemia [22]. 
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Figure 1. Biochemical markers of iron status [10]. 
Table 1. Hemoglobin cut-off levels (g/L) to diagnose anemia. 
Population Non-Anemia 
Anemia 
Mild Moderate Severe 
Children 
6–59 months 
>110 100–109 70–99 <70 
Children 
5–11 years 
>115 110–114 80–109 <80 
Children 
12–14 years 
>120 110–119 80–109 <80 
Non-pregnant women 
(>15 years of age) 
>120 110–119 80–109 <80 
Pregnant women >110 100–109 70–99 <70 
Men (>15 years of age) >130 110–129 80–109 <80 
Iron balance is regulated by absorption in the enterocytes, but once absorbed there is no metabolic 
route for excretion [27] and the major amount of iron entering blood plasma comes from recycling. Iron 
can form free radicals, and excess iron in body tissues can lead to tissue damage [28]. Only small 
amounts of iron are lost through cell shedding and minor bleeding, and these are replaced by the 
absorption of similar amounts by duodenal enterocytes [29]. The main regulator of iron metabolism is 
hepcidin. This hormone inhibits iron absorption, decreases release of iron from macrophages, and 
releases stored iron from hepatocytes. Hepcidin is regulated by three pathways: lower iron stores, 
erythropoietic signals, and inflammation. Body iron deficiency induces low hepcidin synthesis and, 
consequently, iron movement into plasma is enhanced [28,30]. 
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2. Bone Metabolism 
Bone is an active and dynamic connective tissue, formed by cells and the extracellular matrix, which 
continually remodels itself to adapt to the influences of growth and changes in mechanical loads, to 
maintain mineral homoeostasis, and to regulate the bone marrow environment. Bone tissue is largely 
composed of type I collagen and the remaining organic components consist of non-structural proteins 
like osteonectin, osteocalcin, fibronectin, etc. The inorganic phase of bone is mainly composed of 
calcium and phosphate (hydroxyapatite, Ca10(PO4)6(OH)2) [31].  
2.1. Bone Remodeling  
During development and growth, the skeleton is sculpted to achieve its shape and size  
by the removal of bone from one site and deposition at a different one; this process is called  
modeling [32,33]. Once the skeleton has reached maturity, regeneration continues in order to maintain 
skeletal integrity by removing the foci of damaged bone and replacing them with new bone [33]; this 
process is called remodeling and is responsible for the complete regeneration of the adult skeleton every 
10 years [32]. Bone remodeling occurs through the concerted action of a functional cohort of cells called 
the basic multicellular unit (BMU). The BMU consists of the osteoclasts resorbing bone, the osteoblasts 
replacing bone, the osteocytes within the bone matrix, the bone lining cells covering the bone surface, 
and the capillary blood supply [32,34]. Bone remodeling occurs in 4 phases: activation, resorption, 
reversal, and formation [34,35]. 
The activation phase consists of the recruitment of osteoclast precursors (OCP) (from hematopoietic 
stem cells), their differentiation into mature osteoclasts, and their activation (Figure 2) [34,35]. 
Osteoclast activity and formation are dependent on the presence of two different cytokines, which are 
essential and sufficient: macrophage colony-stimulating factors (M-CSF) and receptor activator of  
NF-κB ligand (RANKL). RANKL is expressed by several cell types in bone and bone marrow, including 
osteoblasts, osteocytes, bone marrow stromal cells, and lymphocytes. Osteoblastic cells have been 
thought to be the major cell type that expresses RANKL; however, Nakashima et al. [36] found that 
purified osteocytes express a much higher amount of RANKL and have a greater capacity to support 
osteoclastogenesis in vitro than osteoblasts and bone marrow stromal cells. Osteocytes are cells located 
within the bone matrix and are former osteoblasts that become surrounded by unmineralized matrix 
(osteoid) during bone formation. These cells constitute around 90%–95% of the adult bone cell  
population [37,38] and are now recognized as the major regulator of skeletal activity, capable of sensing 
and integrating mechanical and chemical signals from their environment to regulate both bone formation 
and resorption [37]. The receptor of RANKL in OCP is RANK, which initiates events that result in 
osteoclast differentiation. In contrast, the decoy receptor of RANK, the osteoprotegerin (OPG) produced 
by the osteoblasts, has an essential physiological role as an inhibitor of osteoclast formation [39,40]. 
Another factor required for progenitor cells to differentiate into osteoclasts is M-CSF, which binds to  
c-fms in OCP [41]. 
 
Nutrients 2015, 7 2329 
 
 
Figure 2. Activation phase of bone remodeling. c-fms: M-CSF receptor; M-CSF: 
macrophage colony-stimulating factors; OCP: osteoclast precursor; OPG: osteoprotegerin; 
RANKL: receptor activator of NF-kB ligand; RANK: RANKL receptor. 
Osteoclasts adhere to bone and resorb it by acidification and proteolysis of the bone matrix. In the 
further course of resorption, the osteoclast progenitors are differentiated to fully active osteoclasts that 
dig trenches with a depth of 40–60 μm in the bone. Osteoclast function is regulated both by locally and 
systemic factors: calcitonin, androgens, thyroid hormone, insulin, parathyroid hormone (PTH),  
insulin-like growth factor (IGF)-I, Platelet-derived growth factor (PDGF), inflammation, acidosis, and 
hypoxia [42]. 
The resorption phase is followed by the reversal phase, which is a transition from osteoclast to 
osteoblast activity and comprises the differentiation of osteoblast precursors and the discontinuation of 
bone resorption with osteoclast apoptosis [31]. During this phase, bone-resorbing osteoclasts stimulate 
differentiation of osteoblast precursors, activating bone formation in bone resorption lacunae. In that 
sense, bone resorption may liberate growth factors such as TGF-b, bone morphogenetic proteins 
(BMPs), and insulin-like growth factor (IGF)-II from bone matrix, which in turn activate bone  
formation [43,44].  
Several factors stimulate osteoclast apoptosis, including high extracellular calcium concentrations 
that result from bone degradation [45], estrogens, and pharmacologic doses of bisphosphonates [33].  
After osteoblast activation, osteoblasts lay down new bone material (i.e., collagen type I, osteocalcin, 
osteopontin, etc.) until the resorbed bone is entirely replaced by a new one [31].  
The osteoblast represents a unique bone-forming cell derived from mesenchymal stem cells. These 
cells move in to cover the excavated area and begin the process of new bone formation by secreting 
osteoid, which is eventually mineralized into new bone. This stage lasts the longest, as bone formation 
is slower than bone resorption [34,35]. Finally, the osteoblasts become quiescent at the end of bone 
 
Nutrients 2015, 7 2330 
 
remodeling, and they form flattened lining cells on the bone surface until a new remodeling cycle is 
triggered or become osteocyte cells (as reviewed previously, osteocytes are cells derived from 
osteoblasts embedded in bone) [31]. 
2.2. Biochemical Markers of Bone Remodeling 
Biochemical bone turnover markers are released during bone remodeling and provide a measure of 
the rate of bone metabolism. They comprise enzymes secreted by osteoblasts and osteoclasts during 
remodeling, degradation products formed during resorption, and precursors released during new bone 
formation. They reflect metabolic abnormalities such as accelerated bone turnover (Table 2) [46]. 
Table 2. Biochemical bone turnover markers in serum and urine. 
Bone Resorption Marker Bone Formation Marker 
C-terminal cross-linked telopeptide of type I collagen (CTx) Bone alkaline phosphatase (ALP) 
N-telopeptide cross-linked of type 1 collagen (NTx) Osteocalcin (OC) 
Pyridinoline (PYD) N-terminal propeptide of type I procollagen 
(P1NP) 
Deoxypyridinoline (DPD) C-terminal propeptide of type I procollagen 
(P1CP) 
Hydroxyproline (HYP)  
Tartrat-resistant acid phosphatase type 5b (TRAP 5b)  
3. Role of Iron in Bone Metabolism 
Iron participates in a variety of enzymatic systems in the body, including the enzymes involved in 
collagen synthesis. Collagen is the most abundant protein in animals, and the major component of 
connective tissue [47]. Regarding bone tissue, about 90% of total bone protein is composed of type I 
collagen [31]. For collagen synthesis, first, a three-dimensional stranded structure is assembled, with the 
amino acids glycine and proline as its principal components. This is not yet collagen but its precursor, 
procollagen. Procollagen is then modified by the addition of hydroxyl groups to the amino acids proline 
and lysine. This step is important for later glycosylation and the formation of the triple helix structure of 
collagen. This reaction requires α-ketoglutarate, molecular oxygen, ferrous iron, and a reducing  
agent [48,49]. In this regard, ascorbate reduces the inactive Fe3+ state to the active Fe2+ state [50]. During 
the reaction, α-ketoglutarate is decarboxylated oxidatively to produce succinate and CO2 [48] (Figure 3). 
These hydroxylation reactions are catalyzed by two different enzymes: prolyl-4-hydroxylase [48] and 
lysyl-hydroxylase [49].  
Another mechanism in which iron participates in bone metabolism is through vitamin D activation 
and deactivation. In this pathway, the cytochrome P450 superfamily, a large number of heme-containing 
monooxygenases, plays an important role [51]. 
Vitamin D undergoes two steps of hydroxylation for its activation. The first step occurs in the liver 
and as a result 25-hydroxyvitamin D (25OHD) is produced. This is the first and bounden step in the 
production of the active form of this vitamin [51,52]. This step occurs in the liver and is catalyzed by 
the cythocrome P-450 25-hydroxylase (CYP2R1) [51]. Mutations in CYP2R1 gene lead to low serum 
levels of 25OHD and are associated with rickets (softening and weakening of bones in children, leading 
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to bone deformities and fractures). CYP2R1 deficiency is designated as vitamin D-dependent rickets 
type 1B [53]. 
 
Figure 3. Role of iron in the collagen synthesis. 
The second step occurs in the kidney, producing 1,25-dihydroxyvitamin D (1,25OHD), the bioactive 
form of the vitamin D, which binds to the vitamin D receptor and regulates calcium metabolism. Thus 
this second hydroxylation regulates the level of biologically active vitamin D and plays an important 
role in calcium homeostasis. Active 1,25OHD promotes intestinal calcium and phosphorous absorption, 
phosphate reabsorption in the kidney, and calcium and phosphate release from the bone [52,54,55]. The 
enzyme responsible for this reaction is the 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1). 
Inactivating mutations in CYP27B1 cause vitamin D-dependent rickets type 1A, a rare autosomal 
recessive disorder characterized by the early onset and severe syndrome of rickets [56]. 
Finally, the 1α,25-hydroxyvitamin D 24-hydroxylase (CYP24A1), inactivates the 1,25OHD through 
multiple oxidations of the sterol side chain (Figure 4). Loss of CYP24A1 function usually leads to 
idiopathic infantile hypercalcemia, a rare disease characterized by failure to thrive, vomiting, 
dehydration, and nephrocalcinosis [57]. 
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Figure 4. Vitamin D activation and deactivation by the cytochromes P450. 
Iron is essential for vitamin D metabolism, as all of the vitamin D-related cytochromes catalyze single 
or multiple hydroxylation reactions on specific carbons of the vitamin D substrate using a  
heme-bound iron [58]. 
4. Relationship between Body Iron Levels and Bone Metabolism 
A relationship between iron metabolism and bone was first established from clinical studies that 
observed a higher incidence of osteoporosis and fractures in patients with disorders of iron metabolism 
such as hereditary hemochromatosis, thalassemia, and sickle cell disease [59–61]. 
In healthy populations the relationship between iron status and bone metabolism is controversial. 
Results show positive correlation between serum ferritin and BMD in elderly men but not in  
women [62]. In contrast, there was a negative correlation in women older than 45 years of age [63], and 
no association between BMD and either transferrin saturation or ferritin in men [64]. Buyukbese  
et al. [65] did not observe differences in ferritin levels between osteoporotic postmenopausal women 
and controls. The following sections describe the role of iron overload and iron deficiency on bone 
metabolism and the possible mechanisms involved. 
4.1. Iron Overload and Bone Loss 
Thalassemia refers to a group of inherited disorders of hemoglobin synthesis owing to a defect in the 
ability of erythroblasts to synthesize one or more of the globin chains of hemoglobin. In its more severe 
form (β thalassemia major and α thalassemia major), ineffective erythropoiesis and the subsequent 
hemolytic anemia require chronic transfusion. In this condition, iron overload occurs as a complication 
of chronic transfusion therapy. 
Several bone abnormalities are present in patients with thalassemia major, including the enlargement 
of the head bones, spinal deformities, scoliosis, nerve compression, bone loss, and fractures. Frequently 
they suffer from bone pain. The pathogenesis of osteoporosis is very different form that of bone 
deformity [66]. The reported frequency of osteoporosis, in thalassemia mayor patients, despite adequate 
transfusion and iron chelation therapy, varies from 13.6% to 50% with an additional 45% affected by 
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osteopenia [67]. Multiple factors are involved in the pathogenesis of osteopenia or osteoporosis in 
thalassemia major, such as: delay in sexual maturation, hypothyroidism, parathyroid gland dysfunction, 
accelerated hemopoiesis with progressive bone marrow expansion, diabetes, and low secretion of growth 
hormone or IGF-I [66]. Although endocrine dysfunction has a major role in the development of 
osteoporosis in thalassemia mayor, iron overload due to transfusion and chelation therapy also influence 
bone [68]. 
Genetic hemochromatosis is a hereditary disease characterized by a mutation in the HFE gene, 
C282Y, or H63D, and excessive iron absorption particularly in C282Y homozygous. The prevalence of 
osteoporosis in hemochromatosis has been estimated at between 25.3% and 34.2% [69]. One study 
carried out in men with hemochromatosis observed osteopenia in 78.9% of patients and osteoporosis in 
34.2%, and that femoral neck BMD appeared to fall with rising hepatic iron concentrations [61]. In 
addition, untreated hemochromatosis may lead to various joint complications including arthritis and 
dermoskeleton alterations [64]. 
Sickle cell anemia is another genetic disorder in which sickle hemoglobin leads to tissue hypoxia and 
adverse effects on bone. Patients experience acute episodes (vaso-occlusive bone or joint pain, or acute 
osteomyelitis) as well as chronic bone and joint disorders. Combined, osteopenia and osteoporosis have 
been found in up to 80% of adults with sickle cell disease anemia, but their association with fracture risk 
has not been studied in depth [70–72]. Bone loss has been ascribed in part to bone marrow hyperplasia 
and inflammation secondary to chronic anemia or bone marrow ischemia [71,73,74]. Table 3 
summarizes the effects of iron overload on bone health in humans. 
Table 3. Effects of iron overload on bone health in humans. 
Subjects  Main Results Ref. 
Hemochromatosis Men, n = 38 (13% 
hypogonadal) 
79% osteopenic; 34% osteoporotic [61] 
Hemochromatosis Adults, n = 87 41% osteopenic; 25% osteoporotic, 
Lower BMD and decrease in bone  
formation in patients with higher tissue iron 
[75] 
Thalassemia Adults, n = 80. BMD Negative association between  
ferritin levels and BMD 
[76] 
Thalassemia All, n = 702; n = 312, 
BMD 
Thalassemia major 17% fracture;  
thalassemia intermedia 12% 
[77] 
Thalassemia Adults, n = 41 41% osteoporosis [78] 
Thalassemia Children, n = 18 61% low bone mass [79] 
Sickle cell anemia Adults, n = 17 47% osteopenia; hepatic iron and serum ferritin 
higher in osteopenic than non-osteopenic patients 
[80] 
The main mechanism by which excess iron is harmful to bone is oxidative stress. Tsay et al. [81] 
developed a mouse model of iron overload in which mice were injected chronically with iron dextran in 
two doses, resulting in severe tissue iron overload. Iron loading induced changes in bone composition, 
trabecular and cortical thinning of bone, and bone resorption. Reactive oxygen species ROS and the  
pro-osteoclatogenic cytokines TNF-α and IL-6 increased in a manner correlated with the severity of iron 
overload. Interestingly, treatment with the antioxidant N-acetyl-L-cysteine prevented the development 
of bone abnormalities. In view of these findings, the authors conclude that iron excess leads to increased 
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oxidative stress, which induces inflammatory changes that then mediate bone loss through changes in 
bone resorption.  
Another suggested mechanism by which iron overload may interfere in osteoid maturation and 
mineralization includes the incorporation of iron into crystals of calcium hydroxyapatite, which 
consequently affects the growth of hydroxyapatite crystals and reduces the BMU tensile strength [68,82]. 
In addition, iron itself may have an effect on osteoblastic activity, as demonstrated in vitro [59] and in 
hemochromatosis patients who showed lower markers of bone formation [69]. Finally, iron chelators 
such as deferoxamine inhibit osteoblast and fibroblast proliferation, osteoblast precursor differentiation, 
and collagen formation, and enhance osteoblast apoptosis, especially in patients who receive 
inappropriately high doses of these chelators [68]. 
Table 4. Effects of iron deficiency on bone health in animals and humans. 
Methods Bone Determinations  Effects of Iron Deficiency on Bone Ref. 
Animal studies    
Weanling female rats: Control diet 
Calcium restricted diet 
Iron deficient diet 
Pair-fed to the iron-deficient group 
OC, DPD, serum 1,25OHD, 
BMD, and BMC (total and  
femur), femur strength 
Decreased: BMD, BMC, and femur bone strength  
No change: DPD, OC, and 1,25OHD 
[83] 
Weanling male rats: Control diet 
Iron-deficient diet 
OC, CTx, DPD, BMC,  
and BMD (femur and  
lumbar vertebra) 
Decreased: OC, DPD, BMC, and BMD 
Increased: CTx  
[84] 
Weanling male rats: Control diet 
Iron-free diet 
Pair-fed to the iron-deficient group 
PTH, serum 1,25OHD, IGF-I, 
OC, BMC, and BMD (femur) 
Decreased: OC, DPD, Serum IGF-I,  
BMC, and BMD  
Increased: CTx,  
No change: PTH and IGF-I 
[85] 
Weanling male rats  
Control diet 
Low-Fe diet 
P1NP, TRACP 5b, CTx,  
PTH, 25OHD, and BMC  
(sternum and femur) 
Decreased: P1NP 
Increased: PTH, TRACP 5b, and CTX 
No change: 25OHD, Ca, and P content in sternum  
[86] 
Human studies 
Healthy postmenopausal women  
(n = 242; 40–66 years) 
Dietary Fe and Ca, BMD  Dietary iron positively associated with BMD [87] 
Healthy  postmenopausal women  
(n = 228; 40–65 years) 
BMD at different sites Dietary iron positively associated with BMD only 
in women using hormone replacement therapy 
[88] 
Osteoporotic postmenopausal  
women (n = 455; 66 ± 10 years) 
BMD, ALP, OC, 25OHD Negative correlation between  
transferrin and BMD 
[89] 
Mild iron deficient women  
(n = 41; 18–35 years) 
25OHD, PTH, ALP, NTx Positive association between 25OHD  
and transferrin saturation 
[90] 
Non-anemic women (n = 165;  
18–35 years) 
25OHD, PTH, P1NP, NTx Negative correlations: ferritin and NTx;  
transferrin and P1NP  
[91] 
4.2. Iron Deficiency and Bone Loss 
Iron is essential for cell growth and functioning, thus it is not surprising that deficiency anemia affects 
bone metabolism. In this regard, it is not clear which alteration—iron overload or iron deficiency—may 
have more important health repercussions and a higher impact on public health. Zhao et al. [92] 
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performed an interesting experiment in human osteoblast cells to determine the effects of both excessive 
iron and low iron on osteoblast activity. They concluded that excess iron inhibited osteoblast activity in 
a concentration-dependent manner; mild iron deficiency promotes osteoblast activity but severe low iron 
levels inhibited osteogenesis. Table 4 summarizes the effects of iron deficiency on bone health. 
Reports from animal studies have shown the relationship between dietary iron restriction and bone 
health, and found that severe nutritional iron restriction has a significant impact on bone, affecting BMD, 
bone mineral content (BMC), and femur strength. In several studies decreases in bone formation and/or 
increases in bone resorption markers were found [83,85,86]. These parameters were recovered after 
supplying a normal or high-iron diet [93]. 
In healthy postmenopausal women, a positive association between dietary iron and BMD was  
found [87]. However, the same authors observed in a one year follow-up study that this association was 
only observed in women on hormone replacement therapy [88]. In this line, a positive association 
between ferritin levels and BMD was found in the KNANES study for the whole cohort (men and women 
10–80 years) [94] and for men >65 years [62], but the association was the inverse for women ≥45  
years [94]. Other studies report higher serum transferrin and lower but not significant ferritin levels in 
women with osteoporosis compared to controls [89]. Therefore, the hormonal situation plays a role 
modulating the effects of iron on bone health. 
Our research group studied the iron–bone relationship in menstruating women. They constitute an 
important population group at risk of iron deficiency anemia and additionally they are at the 
physiological stage of achieving peak bone mass [90,91,95]. As shown in Table 5, significant negative 
associations between serum transferrin and P1NP, and between ferritin and NTx were obtained, 
suggesting a relationship between bone turnover and iron status. When the women are divided into three 
groups: iron deficiency anemia (hemoglobin <12 mg/dL; serum ferritin <30 ng/mL), iron deficiency 
(hemoglobin >12 mg/dL; serum ferritin <30 ng/mL), and iron sufficiency (hemoglobin >12 mg/dL; 
serum ferritin >30 ng/mL), NTx was significantly higher in the iron-deficient compared to the iron 
deficiency anemia and iron-sufficient groups (Table 6), which suggest that bone resorption is enhanced 
by mild iron deficiency. This result may be related to the work of Zhao et al. [92] mentioned above, 
which shows that mild iron deficiency promotes osteoblast activity while both excess iron and severe 
iron deficiency inhibit osteoblasts. Therefore, and although the differences between groups in P1NP 
were not significant, it is possible that osteoblast and osteoclast activation are coupled, resulting in higher 
bone resorption, which is faster than bone formation and predominates in this subclinical stage of iron 
deficiency. The underlying mechanisms and consequences of this finding should be further explored. 
Table 5. Correlations between iron and bone remodeling biomarkers in menstruating women. 
 n Transferrin Ferritin Log 
NTx log 220 0.047 −0.237 * 
P1NP 193 −0.254 * 0.055 
Pearson’s correlation controlled for age and BMI; * p ≤ 0.001. 
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Table 6. Bone biomarkers in iron deficiency anemia, iron deficiency, and iron sufficiency groups.  
Parameter 
Iron Deficiency 
Anemia (n = 42) 
Iron Deficiency 
(n = 94) 
Iron Sufficiency 
(n = 84) 
ANOVA p 
25OHD (nmol/L) 56.0 ± 25.0 50.7 ± 25.7 55.1 ± 21.0 NS 
P1NP (ng/mL) 40.4 ± 15.9 54.6 ± 21.7 50.8 ± 19.9 NS 
PTH pg/mL 39.8 ± 14.1 40.5 ± 16.5 38.1 ± 15.4 NS 
NTx (nmol BCF/mmol 
creatinine) 
44.5 ± 26.1 64.5 ± 35.2 * 45.3 ± 38.8 0.001 
Values are mean ± SD. Differences between groups (ANOVA); * Different from anemic and deficient groups 
(p < 0.01) by post hoc Bonferroni test. 
We performed specific interventions in these women. Anemic women were treated with ferrous 
sulfate, and it was found that those who recovered normal hemoglobin levels exhibited a decrease in 
bone remodeling, as both P1NP and NTx were lower at the end of treatment compared to  
baseline [95]. Two nutritional interventions were carried out in iron-deficient women using functional 
foods. One of them studied the effects of consuming an iron-fortified fruit juice compared to placebo. 
This functional food was very efficacious in improving iron status [96]; however, iron formation and 
resorption markers did not change during the 16-week intervention period [90]. The other nutritional 
intervention investigated the effects of an iron- or iron and vitamin D-fortified dairy product  
on iron and bone metabolism. This product did not provide bioavailable iron and iron status did not 
improve [11]; the vitamin D fortification reduced both bone formation and resorption in these women, 
as expected, but the possible effect of iron on bone could not be seen [91]. 
It is difficult to explain why the bones of anemic women responded to the iron recovery, but no 
variation in bone remodeling was observed in the iron-deficient women who consumed the  
iron-fortified fruit juice, or why bones from iron-deficient women treated with vitamin D clearly 
improved. Therefore, further studies in this line are needed.  
5. Mechanisms of the Relationship between Iron Deficiency and Bone Loss 
Different mechanisms by which iron deficiency affects bone have been suggested. On the one hand, 
there is the role of iron as an essential cofactor for hydroxylation of prolyl and lysil residues of 
procollagen, as detailed before (Figure 2). On the other hand, there is its participation in vitamin D 
metabolism through the cytochromes P450 (Figure 3). A third mechanism to be considered is hypoxia. 
A state of hypoxia occurs when oxygen supply to tissues is reduced, as occurs in anemia. Hypoxia is a 
major stimulator of bone resorption, inducing osteoclastogenesis, which is later followed by 
osteoblastogenesis [97,98]. Interestingly, during normoxia, α-ketoglutarate and both molecular oxygen 
and iron are needed for the activity of a prolyl hydroxylase domain protein that acts on the hypoxia 
inducible factor α (HIF-1α) for its degradation, preventing its action. The role of iron in HIF-1α is similar 
to that involved in the collagen synthesis, as indicated previously (Figure 3). Under hypoxia conditions, 
HIF-1α is not degraded and translocates to the nucleus where transcription of >100 genes is  
regulated [48]. Among these genes, erythropoietin (EPO), PDGF, and transferrin are of particular 
interest in exploring the link between iron deficiency anemia and bone health. In this regard, apart from 
the erythropoiesis function, several pleiotropic effects of EPO have been recognized. EPO acts directly 
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or indirectly in the remodeling process [98–100] and has been reported to induce bone resorption in  
mice [101]. 
Finally, metabolic or local acidosis can also induce osteoclast activation and bone loss [97,102]. 
Acidosis can also result from hypoxia and it is widely known that bone resorption is activated under low 
pH in order to release phosphates and restore acid-base equilibrium in extracellular fluid. However, 
recently Okito et al. [102] observed that under acidic conditions osteoblasts tend to change their 
phenotype from osteogenic to osteoclastogenic, demonstrating that both osteoblast and osteoclast 
activities are altered. 
It is important to remember that bone formation is slower than bone resorption, thus a prolonged 
situation of iron deficiency could result in bone loss and increase risk of osteoporosis, with the 
concomitant public health impact. 
6. Hypothesis and Directions for Further Research 
Based on current knowledge, we hypothesize that iron deficiency—with or without anemia—
negatively affects bone through different mechanisms.  
To prove the hypothesis that chronic iron deficiency predisposes patients to bone loss, osteoporosis, 
and risk of fracture, various investigation lines should be developed as there are many unsolved issues. 
It is not known to what extent severe iron deficiency or mild iron deficiency affect bone. The protective 
or aggravating influence of different hormones (EPO, hepcidin, etc.) and factors such as inflammation, 
acidosis, and hypoxia due to anemia or other causes should be investigated. Moreover, genetic aspects 
of the interrelationship between iron and bone are largely unexplored. 
Apart from the in vitro and animal studies, the main work should be done in human prospective 
studies. Hematologic and bone parameters should be determined during periods of several years and in 
different populations, children and adolescents, women at childbearing age and the elderly, with robust 
end points, such as diagnostic of bone disease and fracture. 
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